2.2. Outcomes
ADVERSE EVENTS
The primary outcome (efficacy analysis) was evaluated by determining the percentage of patients with undetectable viral load at weeks 24, 48, and 96 after switching. Virological failure was defined as the presence of an HIV viral load over 50 copies/mL during follow-up.Secondary outcomes were: (a) patients’ immune recovery evolution through measuring total plasma CD4+/CD8+ cells count and CD4+/CD8+ ratio; (b) adverse events throughout the whole follow-up period; and (c) investigating reasons that led clinicians to switch to DTG plus 3TC.